The presence of hepatitis B core antibody is associated with more advanced liver disease in alcoholic patients with cirrhosis

Alcohol. 2013 Nov;47(7):553-8. doi: 10.1016/j.alcohol.2013.07.003. Epub 2013 Sep 13.

Abstract

Background: Liver disease is more severe in patients with chronic hepatitis B virus (HBV) infections and alcohol-induced liver injury. Whether the same is true for alcoholic patients with cirrhosis who have recovered from previous HBV infections remains to be determined.

Objectives: To document the extent of liver disease in alcoholic patients with cirrhosis who test negative for hepatitis B surface antigen (HBsAg) and test positive for antibody to hepatitis B core antigen (anti-HBc).

Methods: Two hundred fifty-four alcoholic patients with cirrhosis were divided into anti-HBc-positive (N = 171) and anti-HBc-negative (N = 83) cohorts. Demographic, clinical, and biochemical features were retrospectively analyzed. Prognostic scores and the prevalence of patients at high risk for short-term mortality were calculated. Logistic regression was used to identify factors associated with an increased risk for short-term mortality.

Results: Jaundice was more common in the anti-HBc-positive cohort (32.2% vs. 18.1%, p = 0.02). This cohort also had higher serum bilirubin (70.9 vs. 50.4 μM/L, p = 0.03), prothrombin times (15.6 vs. 14.4 s, p = 0.01), MELD scores (8.5 vs. 4.6, p = 0.01), i-MELD scores (28.6 vs. 24.7, p = 0.03), MDF scores (14.2 vs. 6.8, p = 0.02) and ABIC scores (7.2 vs. 6.6, p = 0.01). In addition, anti-HBC-positive patients were more often at high risk for short-term mortality (40.4% vs. 26.5%, p = 0.03). Multivariate analysis identified anti-HBc-positive status (OR: 1.84; 95% CI: 1.10-3.36) and alcohol intake ≥150 g/day (OR: 2.01; 95% CI: 1.10-3.66) as independent risk factors for high risk of mortality.

Conclusion: The anti-HBc-positive state is associated with more advanced liver disease in alcoholic patients with cirrhosis. A prospective study including HBV-DNA testing and liver biopsies should be considered to validate and further elucidate these findings.

Keywords: ABIC; ACHE; ALB; ALP; ALT; AST; Alcoholic; Anti HBc; Anti-HBc; Anti-HBe; Anti-HBs; Anti-HCV; DALY; DBIL; GGT; HBV; HBeAg; HCC; Hepatitis B virus; INR and creatinine score; IQR; Liver cirrhosis; MDF; MELD; Maddrey's discriminant function; Mayo End-Stage Liver Disease; PLT; PT; Prognosis; TBIL; alanine aminotransferase; albumin; alkaline phosphatase; antibodies to hepatitis C virus; antibody to HBeAg; antibody to hepatitis B core antigen; antibody to hepatitis B surface antigen; aspartate aminotransferase; bilirubin; cholinesterase; direct bilirubin; disability-adjusted life-years; hepatitis B e antigen; hepatitis B virus; hepatocellular carcinoma; i-MELD; integrated-MELD; interquartile ranges; platelet; prothrombin time; total bilirubin; γ-glutamyltranspeptidase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Hepatitis B Antibodies / blood*
  • Hepatitis B Core Antigens / immunology*
  • Hepatitis B Surface Antigens / immunology
  • Hepatitis B, Chronic / immunology
  • Humans
  • Liver Cirrhosis, Alcoholic / immunology*
  • Liver Cirrhosis, Alcoholic / mortality
  • Liver Cirrhosis, Alcoholic / pathology
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies

Substances

  • Hepatitis B Antibodies
  • Hepatitis B Core Antigens
  • Hepatitis B Surface Antigens